Select Medical (SEM) stockholders clear go-private merger led by insiders and WCAS
Select Medical (SEM) stockholders have approved a go-private merger led by company insiders and Welsh, Carson, Anderson & Stout (WCAS), clearing a key milestone for the deal to close. With the shareholder vote done, the trade now narrows to merger-arb spread compression as the transaction moves toward regulatory clearance and closing.
Select Medical Holdings (SEM) shareholders have voted to approve the go-private merger backed by company insiders and private equity firm Welsh, Carson, Anderson & Stout (WCAS). The transaction would take SEM off public markets, and the shareholder vote represents a significant procedural hurdle now cleared. Exact deal price terms were not re-stated in the headline, but with the vote passed, the path to closing has materially de-risked.
SEM is a sizable healthcare services operator with roughly $5.5B in annual revenue growing at 5.1% year-over-year, though net margins are thin at 3.9% and diluted EPS sits at $1.16. The insider-led nature of the deal — with management and WCAS as the acquirer group — reduces the risk of a strategic bidder emerging to break the deal, but it also means shareholders are locked into the negotiated terms.
For traders, this is now a classic merger-arb setup: the question is how much spread remains between the current stock price and the deal consideration, and what residual deal-break risk justifies that spread. With shareholder approval in hand, the remaining risks are regulatory sign-off and financing close.
The bull case for arb longs is straightforward — shareholder approval is the biggest vote-of-confidence milestone, and insider + PE backing reduces deal-break probability sharply. The bear case centers on any lingering regulatory review timeline or financing conditions that could delay or derail closing, which would expose the stock to a significant re-rating back toward fundamental value on thin 3.9% net margins.
With SEM shareholders having approved the go-private merger, the question for SEM is how much spread to deal consideration remains and whether residual regulatory or financing risk justifies holding the arb position into close.
Shareholder approval is the largest binary risk in any go-private deal and it has now been cleared. With insiders and WCAS as the buyer group, a topping bid or deal-walk is unlikely, concentrating remaining risk on regulatory review timelines. If the arb spread is still 1-2%+ to deal consideration, the risk/reward on a spread compression trade is favorable given the reduced deal-break probability.
Regulatory delay or denial, or a financing condition failure, would send SEM back toward fundamental value — thin 3.9% net margins and $1.16 EPS on $5.5B revenue suggest the pre-deal standalone valuation offers limited support at deal-adjacent prices.
CoverageSource: Stock Titan · Published here FRI, JUN 26 · 5:23 PM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
Shareholder approval — the highest-stakes merger milestone — is now cleared, and the insider + WCAS structure means no management opposition or competing bid risk remains, making spread compression toward deal price the high-probability outcome.
If regulatory review drags materially or financing conditions are not met, SEM would re-rate sharply lower given thin 3.9% net margins leave limited standalone fundamental support at current deal-adjacent prices.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →